Yeast display technology enables rapid discovery of low-nanomolar macrocyclic peptide inhibitors of human angiotensin-converting enzyme 2

Résumé fourni par la source

Macrocyclic peptides are valuable molecular formats for drug development, positioning themselves as a bridge between small-molecules and larger biologics due to their favourable pharmacological properties. Here we describe the discovery of low-nanomolar macrocyclic peptide inhibitors of human angiotensin-converting enzyme 2 (hACE2) by quantitatively screening millions of structurally diverse disulfide-cyclised peptide ligands using yeast display technology. The most potent yeast-encoded macrocyclic peptide exhibits a KD of 16.1 nM and inhibits hACE2 with an IC50 of 7.5 nM. These binding affinities and inhibitory potencies are comparable to those of other cyclic peptides discovered using well-established phage and mRNA display technologies. Determination of the crystal structure of the macrocyclic peptide in complex with hACE2 reveals a rigid β-hairpin structure that shows a different binding mode compared to previously reported inhibitors. Thus, yeast display is a valid technology to rapidly generate macrocyclic peptides with desired binding properties for the development of potential therapeutics.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.